A small molecule drug candidate from Algiax Pharmaceuticals can reduce excitability of neurons in relation to chronic pain, dampening signal and reducing pain, a study shows.
Data Monitoring Committee recommends continuation of the study with no safety alerts within the study population Company is ramping up patient recruitment by doubling number of countries